.

Pharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

LEXISCAN Drug Profile

« Back to Dashboard

Which patents cover Lexiscan, and what substitute generic drugs are available?

Lexiscan is a drug marketed by Astellas and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-eight patent family members in twenty-five countries.

The generic ingredient in LEXISCAN is regadenoson. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the regadenoson profile page.

Summary for Tradename: LEXISCAN

Patents:17
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list25
Clinical Trials: see list33
Patent Applications: see list47
Drug Prices:see details
DailyMed Link:LEXISCAN at DailyMed

Pharmacology for Tradename: LEXISCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes6,403,567► SubscribeYY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes8,106,183► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes7,683,037► Subscribe ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes9,085,601► SubscribeY ► Subscribe
Astellas
LEXISCAN
regadenoson
SOLUTION;INTRAVENOUS022161-001Apr 10, 2008RXYesYes8,133,879► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: LEXISCAN

Drugname Dosage Strength RLD Submissiondate
regadenosonInjection0.08 mg/mL, 5 mL vialLexiscan4/10/2012

Non-Orange Book Patents for Tradename: LEXISCAN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,956,179Process for preparing an A2A-adenosine receptor agonist and its polymorphs► Subscribe
8,278,435N-pyrazole A2A receptor agonists► Subscribe
9,163,057Methods of myocardial perfusion imaging► Subscribe
8,906,878Myocardial perfusion imaging methods and compositions► Subscribe
8,268,988Process for preparing an A2A-adenosine receptor agonist and its polymorphs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LEXISCAN

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)0162979► Subscribe
China101379073► Subscribe
South Korea20130130868► Subscribe
Luxembourg91785► Subscribe
European Patent Office1989214► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LEXISCAN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00005Denmark► Subscribe
90003-2.LSweden► SubscribePRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906
C/GB11/005United Kingdom► SubscribePRODUCT NAME: REGADENOSON; REGISTERED: UK EU/1/10/643/001 20100906
00477Netherlands► SubscribePRODUCT NAME: REGADENOSON ALSMEDE FARMACEUTISCHE AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
2011Austria► SubscribePRODUCT NAME: REGADENOSON UND DESSEN SALZE; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc